Metastatic Pancreatic Cancer clinical trials

Explore recruiting metastatic pancreatic cancer clinical trials.

Recruiting metastatic pancreatic cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Pancreatic Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipaltin (mFOLFIRINOX) in non pretreated metastatic PAncreatic Cancer.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Metastatic Pancreatic Cancer trials by city

Metastatic Pancreatic Cancer clinical trials

Recruiting metastatic pancreatic cancer studies right now

Intravital Microscopy in Human Solid Tumors

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Also recruiting in Europe

Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preference cohort

DOVIPA, a phase II study evaluating efficacy and safety of DOstarlimab and oral VItamin D3 with folinic acid, 5FU, Irinotecan plus oxalipaltin (mFOLFIRINOX) in non pretreated metastatic PAncreatic Cancer.

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)

Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations

Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study

Metastatic Pancreatic Cancer trials by city

Other conditions